Stockhammer, Florian

[["dc.bibliographiccitation.firstpage","15"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Neuro-Oncology"],["dc.bibliographiccitation.lastpage","22"],["dc.bibliographiccitation.volume","109"],["dc.contributor.author","Ahmadi, Rezvan"],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Becker, Natalia"],["dc.contributor.author","Hohlen, Katarina"],["dc.contributor.author","Misch, Martin"],["dc.contributor.author","Christians, Arne"],["dc.contributor.author","Dictus, Christine"],["dc.contributor.author","Herold-Mende, Christel"],["dc.contributor.author","Capper, David"],["dc.contributor.author","Unterberg, Andreas"],["dc.contributor.author","von Deimling, Andreas"],["dc.contributor.author","Wick, Wolfgang"],["dc.contributor.author","Hartmann, Christian"],["dc.date.accessioned","2018-11-07T09:07:48Z"],["dc.date.available","2018-11-07T09:07:48Z"],["dc.date.issued","2012"],["dc.description.abstract","Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) have been identified in approximately 70-80 % of astrocytomas and oligodendrogliomas of WHO grades II and III, and in secondary glioblastomas. In addition, a low incidence of IDH2 mutations has been detected in these tumors, and the occurence of IDH1 and IDH2 mutations is mutually exclusive. For patients with anaplastic gliomas and glioblastomas with IDH1 mutations, overall survival was significantly longer than for patients with wild-type tumours. However, the prognostic value of IDH1 in low-grade gliomas remains ambiguous. IDH1 codon 132 and IDH2 codon 172 mutation status were determined by direct sequencing for a retrospective series of 100 patients with histologically diagnosed Astrocytomas WHO Grad II (A II), and investigated for association with patient outcome. For the patient cohort analysed, median progression-free survival (PFS) was 44.6 months (95 %-CI 1.0-267.0), time to progression (median time to malignant progression (TtMP) was 74.9 months (95 %-CI 1.6-236.2), and median overall survival (OS) was 81.4 months (95 %-CI 5.5-274.8). IDH1 mutations were identified in 79 % of the patients. IDH2 mutations were not observed. Univariate and multivariate analysis revealed no association between IDH1 mutation status and PFS, TtMP, and OS. Furthermore, there were no significant differences regarding PFS, TtMP, and OS between patients with and without IDH1 mutations who did not receive adjuvant treatment. The prognostic value of IDH1 mutations in low-grade astrocytomas is rather low compared with that in high-grade gliomas."],["dc.identifier.doi","10.1007/s11060-012-0863-y"],["dc.identifier.isi","000306953100003"],["dc.identifier.pmid","22528790"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25885"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0167-594X"],["dc.title","No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Wick, Wolfgang"],["dc.contributor.author","Roth, Patrick"],["dc.contributor.author","Wiestler, Benedikt"],["dc.contributor.author","Hartmann, Christian"],["dc.contributor.author","Hau, Peter"],["dc.contributor.author","Nakamura, Makoto"],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Sabel, Michael"],["dc.contributor.author","Koeppen, Susanne"],["dc.contributor.author","Ketter, Ralf"],["dc.contributor.author","Vajkoczy, Peter"],["dc.contributor.author","Eyupoglus, Ilker"],["dc.contributor.author","Kaendler, Stephen"],["dc.contributor.author","Kalff, Rolf"],["dc.contributor.author","Galldiks, Norbert"],["dc.contributor.author","Schmidt-Graf, Friederike"],["dc.contributor.author","von Deimling, Andreas"],["dc.contributor.author","Platten, Michael"],["dc.contributor.author","Reifenberger, Guido"],["dc.contributor.author","Weller, Michael"],["dc.date.accessioned","2018-11-07T09:57:08Z"],["dc.date.available","2018-11-07T09:57:08Z"],["dc.date.issued","2015"],["dc.identifier.isi","000358036900460"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37097"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)"],["dc.relation.eventlocation","Chicago, IL"],["dc.relation.issn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e0229274"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Behling, Felix"],["dc.contributor.author","Barrantes-Freer, Alonso"],["dc.contributor.author","Behnes, Carl Ludwig"],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Adel-Horowski, Antonia"],["dc.contributor.author","Rodríguez-Villagra, Odir Antonio"],["dc.contributor.author","Barboza, Miguel Angel"],["dc.contributor.author","Brück, Wolfgang"],["dc.contributor.author","Lehmann, Ulrich"],["dc.contributor.author","Stadelmann, Christine"],["dc.contributor.author","Hartmann, Christian"],["dc.contributor.editor","Hjelmeland, Anita B."],["dc.date.accessioned","2021-04-14T08:27:01Z"],["dc.date.available","2021-04-14T08:27:01Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1371/journal.pone.0229274"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82143"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1932-6203"],["dc.title","Expression of Olig2, Nestin, NogoA and AQP4 have no impact on overall survival in IDH-wildtype glioblastoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","194"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Seizure"],["dc.bibliographiccitation.lastpage","197"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Misch, Martin"],["dc.contributor.author","Helms, Hans-Joachim"],["dc.contributor.author","Lengler, Ulrike"],["dc.contributor.author","Prall, Friedrich"],["dc.contributor.author","von Deimling, Andreas"],["dc.contributor.author","Hartmann, Christian"],["dc.date.accessioned","2018-11-07T09:11:43Z"],["dc.date.available","2018-11-07T09:11:43Z"],["dc.date.issued","2012"],["dc.description.abstract","Introduction: Seizures are the most common initial symptom in patients with low-grade glioma and their occurrence strongly depends on the tumor location. The majority of low-grade gliomas reveal mutations in the genes encoding isocitrate-dehydrogenase 1 (IDH1) or 2 (IDH2). These mutations are associated with metabolic changes that are potentially epileptogenic. We investigated the correlation between IDH1/2 mutations and tumor localization and seizure as the initial symptom. Materials and methods: This retrospective study included patients with a diagnosis of WHO grade II astrocytoma and cortical infiltration and in whom initial symptoms were documented and biopsy tissue was available for 1DH1/2 analysis. IDH1/2 mutation analysis was performed by direct sequencing or by immunohistochemistry with an antibody which detects mutated protein IDH1 R132H. Sequencing was carried out if immunohistochemistry was negative. 1DH1/2 status was defined as mutated if either of these investigations were positive. Results: Seventy-nine patients were included. IDH1 or IDH2 mutation was present in 63 (80%) patients who on average were younger than patients without IDH1/2 mutation (40 vs. 47 years, p = 0.0331, t-test). IDH1/2 mutations were associated with frontal tumor location (p = 0.0202). All 12 tumors in the insula revealed IDH1/2 mutations. Seizure as the initial symptom was recorded in 57 (72%) patients and was associated with IDH1 or IDH2 mutation by multivariate analysis (OR 22.563, p = 0.0019). Conclusion: In WHO grade II astrocytomas, IDH1/2 mutations mostly occur in tumors infiltrating the frontal lobe. Seizure as the initial symptom is associated with IDH1 or IDH2 mutation. (C) 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.seizure.2011.12.007"],["dc.identifier.isi","000302449700009"],["dc.identifier.pmid","22217666"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26783"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","W B Saunders Co Ltd"],["dc.relation.issn","1059-1311"],["dc.title","IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1529"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Neuro-Oncology"],["dc.bibliographiccitation.lastpage","1537"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Wick, Wolfgang"],["dc.contributor.author","Roth, Patrick"],["dc.contributor.author","Hartmann, Christian"],["dc.contributor.author","Hau, Peter"],["dc.contributor.author","Nakamura, Makoto"],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Sabel, Michael C."],["dc.contributor.author","Wick, Antje"],["dc.contributor.author","Koeppen, Susanne"],["dc.contributor.author","Ketter, Ralf"],["dc.contributor.author","Vajkoczy, Peter"],["dc.contributor.author","Eyupoglu, Ilker"],["dc.contributor.author","Kalff, Rolf"],["dc.contributor.author","Pietsch, Torsten"],["dc.contributor.author","Happold, Caroline"],["dc.contributor.author","Galldiks, Norbert"],["dc.contributor.author","Schmidt-Graf, Friederike"],["dc.contributor.author","Bamberg, Michael"],["dc.contributor.author","Reifenberger, Guido"],["dc.contributor.author","Platten, Michael"],["dc.contributor.author","von Deimling, Andreas"],["dc.contributor.author","Meisner, Christoph"],["dc.contributor.author","Wiestler, Benedikt"],["dc.contributor.author","Weller, Michael"],["dc.date.accessioned","2018-11-07T10:06:29Z"],["dc.date.available","2018-11-07T10:06:29Z"],["dc.date.issued","2016"],["dc.description.abstract","Background. Optimal treatment and precise classification for anaplastic glioma are needed. Methods. The objective for long-term follow-up of NOA-04 is to optimize the treatment sequence for patients with anaplastic gliomas. Patients were randomized 2: 1: 1 to receive the standard radiotherapy (RT) (arm A), procarbazine, lomustine and vincristine (PCV) (arm B1), or temozolomide (TMZ) (arm B2). Results. Primary endpoint was time-to-treatment-failure (TTF), defined as progression after 2 lines of therapy or any time before if no further therapy was administered. Exploratory analyses examined associations of molecular marker status with TTF, progression-free survival (PFS), and overall survival (OS). At 9.5 (95% CI: 8.6-10.2) years, no difference between arms (A vs B1/B2) was observed: median TTF (4.6 [3.4-5.1] y vs 4.4 [3.3-5.3) y), PFS (2.5 [1.3-3.5] y vs 2.7 [1.9-3.2] y), and OS (8 [5.5-10.3] y vs 6.5 [5.4-8.3] y). Oligodendroglial versus astrocytic histology-but more so the subgroups according to CpG island methylator phenotype (CIMP) and 1p/19q co-deletion status-revealed a strong prognostic value of CIMPpos with (CIMPcodel) versus without 1p/19 co-deletion (CIMPnon-codel) versus CIMPneg. but no differential efficacy of RT versus chemotherapy for any of the endpoints. PFS was better for PCV-than for TMZ-treated patients with CIMPcodel tumors (HR B1 vs B2 0.39 [0.17-0.92], P = .31). In CIMPneg. tumors, hypermethylation of the O6-methyl-guanyl-DNA methyltransferase promoter (MGMT) provided a risk reduction for PFS with chemotherapy. Conclusions. There is no differential activity of primary chemotherapy versus RT in any subgroup of anaplastic glioma. Molecular diagnosis is superior to histology. Trial Registration: clinicaltrials.gov Identifier: NCT00717210."],["dc.identifier.doi","10.1093/neuonc/now133"],["dc.identifier.isi","000387330300009"],["dc.identifier.pmid","27370396"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39103"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1523-5866"],["dc.relation.issn","1522-8517"],["dc.title","Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]